162 related articles for article (PubMed ID: 36865172)
1. New tuberculosis vaccines in India: Modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01
Clark RA; Weerasuriya CK; Portnoy A; Mukandavire C; Quaife M; Bakker R; Scarponi D; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
medRxiv; 2023 Jul; ():. PubMed ID: 36865172
[TBL] [Abstract][Full Text] [Related]
2. New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01
Clark RA; Weerasuriya CK; Portnoy A; Mukandavire C; Quaife M; Bakker R; Scarponi D; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
BMC Med; 2023 Aug; 21(1):288. PubMed ID: 37542319
[TBL] [Abstract][Full Text] [Related]
3. The potential health and economic impacts of new tuberculosis vaccines under varying delivery strategies in Delhi and Gujarat, India: a modelling study.
Clark RA; Portnoy A; Weerasuriya CK; Sumner T; Bakker R; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
medRxiv; 2023 Sep; ():. PubMed ID: 37808744
[TBL] [Abstract][Full Text] [Related]
4. Modelling the health and economic impacts ofM72/AS01
Sumner T; Clark RA; Mukandavire C; Portnoy A; Weerasuriya CK; Bakker R; Scarponi D; Hatherill M; Menzies NA; White RG
Vaccine; 2024 Feb; 42(6):1311-1318. PubMed ID: 38307747
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of routine adolescent vaccination with an M72/AS01
Harris RC; Quaife M; Weerasuriya C; Gomez GB; Sumner T; Bozzani F; White RG
Nat Commun; 2022 Feb; 13(1):602. PubMed ID: 35105879
[TBL] [Abstract][Full Text] [Related]
6. Phase 2b Controlled Trial of M72/AS01
Van Der Meeren O; Hatherill M; Nduba V; Wilkinson RJ; Muyoyeta M; Van Brakel E; Ayles HM; Henostroza G; Thienemann F; Scriba TJ; Diacon A; Blatner GL; Demoitié MA; Tameris M; Malahleha M; Innes JC; Hellström E; Martinson N; Singh T; Akite EJ; Khatoon Azam A; Bollaerts A; Ginsberg AM; Evans TG; Gillard P; Tait DR
N Engl J Med; 2018 Oct; 379(17):1621-1634. PubMed ID: 30280651
[TBL] [Abstract][Full Text] [Related]
7. Final Analysis of a Trial of M72/AS01
Tait DR; Hatherill M; Van Der Meeren O; Ginsberg AM; Van Brakel E; Salaun B; Scriba TJ; Akite EJ; Ayles HM; Bollaerts A; Demoitié MA; Diacon A; Evans TG; Gillard P; Hellström E; Innes JC; Lempicki M; Malahleha M; Martinson N; Mesia Vela D; Muyoyeta M; Nduba V; Pascal TG; Tameris M; Thienemann F; Wilkinson RJ; Roman F
N Engl J Med; 2019 Dec; 381(25):2429-2439. PubMed ID: 31661198
[TBL] [Abstract][Full Text] [Related]
8. The Systematic Review and Meta-Analysis on the Immunogenicity and Safety of the Tuberculosis Subunit Vaccines M72/AS01
Ullah I; Bibi S; Ul Haq I; Safia ; Ullah K; Ge L; Shi X; Bin M; Niu H; Tian J; Zhu B
Front Immunol; 2020; 11():1806. PubMed ID: 33133057
[No Abstract] [Full Text] [Related]
9. Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study.
Gillard P; Yang PC; Danilovits M; Su WJ; Cheng SL; Pehme L; Bollaerts A; Jongert E; Moris P; Ofori-Anyinam O; Demoitié MA; Castro M
Tuberculosis (Edinb); 2016 Sep; 100():118-127. PubMed ID: 27553419
[TBL] [Abstract][Full Text] [Related]
10. New tuberculosis vaccines: advances in clinical development and modelling.
Weerasuriya CK; Clark RA; White RG; Harris RC
J Intern Med; 2020 Dec; 288(6):661-681. PubMed ID: 33128834
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting.
Penn-Nicholson A; Geldenhuys H; Burny W; van der Most R; Day CL; Jongert E; Moris P; Hatherill M; Ofori-Anyinam O; Hanekom W; ; Bollaerts A; Demoitie MA; Kany Luabeya AK; De Ruymaeker E; Tameris M; Lapierre D; Scriba TJ
Vaccine; 2015 Jul; 33(32):4025-34. PubMed ID: 26072017
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial.
Kumarasamy N; Poongulali S; Beulah FE; Akite EJ; Ayuk LN; Bollaerts A; Demoitié MA; Jongert E; Ofori-Anyinam O; Van Der Meeren O
Medicine (Baltimore); 2018 Nov; 97(45):e13120. PubMed ID: 30407329
[TBL] [Abstract][Full Text] [Related]
13. Making wider use of the world's most widely used vaccine: Bacille Calmette-Guerin revaccination reconsidered.
Dye C
J R Soc Interface; 2013 Oct; 10(87):20130365. PubMed ID: 23904584
[TBL] [Abstract][Full Text] [Related]
14. Potential implementation strategies, acceptability, and feasibility of new and repurposed TB vaccines.
Pelzer PT; Seeley J; Sun FY; Tameris M; Tao L; Yanlin Z; Moosan H; Weerasuriya C; Asaria M; Jayawardana S; White RG; Harris RC
PLOS Glob Public Health; 2022; 2(5):e0000076. PubMed ID: 36962104
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and Safety of the M72/AS01
Ji Z; Jian M; Chen T; Luo L; Li L; Dai X; Bai R; Ding Z; Bi Y; Wen S; Zhou G; Abi ME; Liu A; Bao F
Front Immunol; 2019; 10():2089. PubMed ID: 31552037
[No Abstract] [Full Text] [Related]
16. A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults.
Montoya J; Solon JA; Cunanan SR; Acosta L; Bollaerts A; Moris P; Janssens M; Jongert E; Demoitié MA; Mettens P; Gatchalian S; Vinals C; Cohen J; Ofori-Anyinam O
J Clin Immunol; 2013 Nov; 33(8):1360-75. PubMed ID: 24142232
[TBL] [Abstract][Full Text] [Related]
17. Non-clinical evaluation of local and systemic immunity induced by different vaccination strategies of the candidate tuberculosis vaccine M72/AS01.
Ouaked N; Demoitié MA; Godfroid F; Mortier MC; Vanloubbeeck Y; Temmerman ST
Tuberculosis (Edinb); 2023 Dec; 143():102425. PubMed ID: 38180028
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial.
Idoko OT; Owolabi OA; Owiafe PK; Moris P; Odutola A; Bollaerts A; Ogundare E; Jongert E; Demoitié MA; Ofori-Anyinam O; Ota MO
Tuberculosis (Edinb); 2014 Dec; 94(6):564-78. PubMed ID: 25305000
[TBL] [Abstract][Full Text] [Related]
19. Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.
Leroux-Roels I; Forgus S; De Boever F; Clement F; Demoitié MA; Mettens P; Moris P; Ledent E; Leroux-Roels G; Ofori-Anyinam O;
Vaccine; 2013 Apr; 31(17):2196-206. PubMed ID: 22643213
[TBL] [Abstract][Full Text] [Related]
20. Designing tuberculosis vaccine efficacy trials - lessons from recent studies.
Ginsberg AM
Expert Rev Vaccines; 2019 May; 18(5):423-432. PubMed ID: 30892969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
